key: cord-0985057-ozs38rn1
authors: Marlet, Julien; Gatault, Philippe; Maakaroun, Zoha; Longuet, Hélène; Stefic, Karl; Handala, Lynda; Eymieux, Sébastien; Gyan, Emmanuel; Dartigeas, Caroline; Gaudy-Graffin, Catherine
title: Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia
date: 2021-09-23
journal: Vaccines (Basel)
DOI: 10.3390/vaccines9101055
sha: 6a4b59d5b822308d8f1b361fec55dd8e6473cc22
doc_id: 985057
cord_uid: ozs38rn1

The impact of a third dose of COVID-19 vaccine on antibody responses is unclear in immunocompromised patients. The objective of this retrospective study was to characterize antibody responses induced by a third dose of mRNA COVID-19 vaccine in 160 kidney transplant recipients and 20 patients treated for chronic lymphocytic leukemia (CLL). Prevalence of anti-spike IgG ≥ 7.1 and ≥ 30 BAU/mL after the third dose were 47% (75/160) and 39% (63/160) in kidney transplant recipients, and 57% (29/51) and 50% (10/20) in patients treated for CLL. Longitudinal follow-up identified a moderate increase in SARS-CoV-2 anti-spike IgG levels after a third dose of vaccine in kidney transplant recipients (0.19 vs. 5.28 BAU/mL, p = 0.03) and in patients treated for CLL (0.63 vs. 10.7 BAU/mL, p = 0.0002). This increase in IgG levels had a limited impact on prevalence of anti-spike IgG ≥ 30 BAU/mL in kidney transplant recipients (17%, 2/12 vs. 33%, 4/12, p = 0.64) and in patients treated for CLL (5%, 1/20 vs. 45%, 9/20, p = 0.008). These results highlight the need for vaccination of the general population and the importance of non-medical preventive measures to protect immunocompromised patients.

Vaccine effectiveness against symptomatic COVID-19 was estimated at between 70 and 97% after two doses of COVID-19 vaccine in immunocompetent patients [1] [2] [3] . In contrast, few immunocompromised patients have been enrolled in COVID-19 phase 3 clinical trials and vaccine effectiveness in this population remains unclear. In a recent observational study, solid organ transplant recipients had an 82-fold higher risk of breakthrough infection and a 485-fold higher risk of breakthrough infection with associated hospitalization and death [4] . Antibody responses after two doses of COVID-19 vaccine, defined as anti-spike IgG seroconversion, are impaired in these patients [5] . They were estimated between 38 to 42% for kidney transplant patients [5, 6] and between 23 to 52% for patients with chronic lymphocytic leukemia, despite the fact that most of these CLL patients were not undergoing cancer therapy [7] [8] [9] . The impact of a third dose of COVID-19 vaccine on antibody responses is unclear in these patients. Response rates to a third dose ranged between 47 and 68% in kidney transplant recipients [10] [11] [12] and limited data are available in patients treated for chronic lymphocytic leukemia (CLL). The objective of this retrospective study was to characterize antibody responses induced by a third dose of mRNA COVID-19 vaccine in 160 kidney transplant recipients and 20 patients treated for CLL.

SARS-CoV-2 anti-spike IgG was tested for all patients at least 21 days after the second and/or third dose of mRNA COVID-19 vaccine, using a SARS-CoV-2 IgG II Quant assay on an Alinity i system (Abbott). Assay results in AU/mL were converted into BAU/mL (international standard units [13] ) using a conversion factor of 0.142, according to the manufacturer's recommendations. We defined responders as patients with positive SARS-CoV-2 IgG, corresponding to levels ≥ 7.1 binding antibody units (BAU)/mL, according to the manufacturer's recommendations and previous studies [14] [15] [16] [17] [18] . This interpretation is limited by its lack of association with vaccine effectiveness and its lack of comparability with other assays, using different cut-offs. As such, results were also compared with a cut-off of 30 BAU/mL, recently associated with 50% vaccine effectiveness against symptomatic COVID-19 in immunocompetent patients [19] . All calculations were performed with Graph-Pad Prism 9.0 using Wilcoxon test (paired values), Mann-Whitney (unpaired values) and Fisher's exact test (binomial variables). p-values < 0.05 (2-sided) were considered significant.

Prevalence of positive SARS-CoV-2 anti-spike IgG (≥7.1 BAU/mL) in kidney transplant recipients tested either after the second (n = 97) or third dose (n = 160) of COVID-19 vaccine was not significantly different (43%, 42/97 vs. 47%, 75/160, p = 0.61, Table 1 ). Prevalence of SARS-CoV-2 anti-spike IgG ≥ 30 BAU/mL was also not significantly different between these two groups (30%, 29/97 vs. 39%, 63/160, p = 0.14). SARS-CoV-2 anti-spike median IgG levels were not significantly different between these two groups (2.7 vs. 5.5 BAU/mL, p = 0.42, Figure 1 ).

In contrast, when considering only the 12 patients with longitudinal follow-up after both the second and third dose, an increase in anti-spike IgG levels was observed (0.19 vs. 5.28 BAU/mL, p = 0.03, Figure 1 ). In this subgroup, prevalence of positive SARS-CoV-2 anti-spike IgG and anti-spike IgG ≥ 30 BAU/mL did not increase after the third dose (17%, 2/12 vs. 42%, 5/12, p = 0.37 and 17%, 2/12 vs. 33%, 4/12, p = 0.64).

Age was associated with poor response to COVID-19 vaccines (>65 year, p = 0.02) but a history of COVID-19 RT-PCR was associated with better responses (p = 0.04, Table 1 ). Nine patients had a history of COVID-19, which occurred at a median of 206 days (IQR: 168-248) before the measurement of SARS-CoV-2 anti-spike IgG.

The third dose of vaccine was injected at a median of 43 days (IQR: 33-63) after the second dose. SARS-CoV-2 anti-spike IgG was measured at a median of 95 days (IQR: 48-124) and 52 days (IQR: 34-76) after the second and third dose of vaccine, respectively. 

In 12 kidney transplant recipients with longitudinal follow-up, a moderate increase in SARS-CoV-2 anti-spike IgG levels was observed after the third dose of COVID-19 vaccine (0.19 vs. 5.28 BAU/mL, p = 0.03). This increase in IgG levels had no significant impact on the prevalence of anti-spike IgG ≥ 30 BAU/mL (17%, 2/12 vs. 33%, 4/12, p = 0.64). In 20 patients treated for CLL with longitudinal follow-up, a moderate increase in SARS-CoV-2 anti-spike IgG levels was observed after the third dose of COVID-19 vaccine (0.63 vs. 10.7 BAU/mL, p = 0.0002). This resulted in an increase in the prevalence of anti-spike IgG ≥ 30 BAU/mL (5%, 1/20 vs. 45%, 9/20, p = 0.008). When considering all patients, with or without longitudinal follow-up, prevalence of anti-spike IgG ≥ 30 BAU/mL after the third dose was 39% (63/160) in kidney transplant recipients and 50% (10/20) in patients treated for CLL. Overall, this suggests that a third dose of COVID-19 vaccine in immunocompromised patients can increase antibody levels. Still, this increase might not be clinically relevant because few patients reached anti-spike IgG levels ≥ 30 BAU/mL, previously associated with 50% vaccine effectiveness [19] . These results are in line with other studies in kidney transplant recipients [10] [11] [12] and provide new data regarding patients with CLL.

In kidney transplant recipients, our results confirm the association between young age (< 65 years) and response to COVID-19 vaccines (p = 0.02) [6, 20] and suggest a better response in patients with a history of COVID-19 (p = 0.04). In patients treated for CLL, our results confirm the association between treatment with tyrosine kinase inhibitors or venetoclax and non-response to COVID-19 vaccines (p = 0.007) [8] .

One limitation of our study is the small number of patients with longitudinal followup. Indeed, antibody responses in immunocompromised patients are probably too heterogeneous to compare groups of unpaired patients. Other limitations of our study are the lack of antibody measurements prior to vaccination, the lack of in vitro investigation of neutralizing Ab titers, especially against circulating variants, and cellular responses. [19] ; black bars, medians. * p < 0.05; *** p < 0.001.

Prevalence of positive SARS-CoV-2 anti-spike IgG and prevalence of SARS-CoV-2 anti-spike IgG ≥ 30 BAU/mL in 51 patients treated for CLL did not increase between the second and third dose of vaccine (57%, 29/51 vs. 50%, 10/20, p = 0.61 and 45%, 23/51 vs. 45%, 9/20, p = 1.0, Table 1 ). SARS-CoV-2 anti-spike median IgG levels were comparable between these two groups (12.9 vs. 10.7 BAU/mL, p = 0.32, Figure 1 ).

In contrast, when considering only the 20 patients with longitudinal follow-up after both the second and third dose, we observed an increase in anti-spike IgG levels (0.63 vs. 10.7 BAU/mL, p = 0.0002, Figure 1 ) and an increase in the prevalence of anti-spike IgG ≥ 30 BAU/mL (5%, 1/20 vs. 45%, 9/20, p = 0.008). In this subgroup, prevalence of positive SARS-CoV-2 anti-spike IgG did not increase after the third dose (20%, 4/20 vs. 50%, 10/20, p = 0.10).

Treatment with tyrosine kinase inhibitors or venetoclax was associated with poor response to the second dose of COVID-19 vaccine (p = 0.007, Table 1 ). The third dose of vaccine was injected at a median of 63 days (IQR: 48-81) after the second dose. SARS-CoV-2 anti-spike IgG was measured at a median of 43 days (IQR: 36-57) and 42 days (IQR: 31-45) after the second and third dose of vaccine, respectively.

In 12 kidney transplant recipients with longitudinal follow-up, a moderate increase in SARS-CoV-2 anti-spike IgG levels was observed after the third dose of COVID-19 vaccine (0.19 vs. 5.28 BAU/mL, p = 0.03). This increase in IgG levels had no significant impact on the prevalence of anti-spike IgG ≥ 30 BAU/mL (17%, 2/12 vs. 33%, 4/12, p = 0.64). In 20 patients treated for CLL with longitudinal follow-up, a moderate increase in SARS-CoV-2 anti-spike IgG levels was observed after the third dose of COVID-19 vaccine (0.63 vs. 10.7 BAU/mL, p = 0.0002). This resulted in an increase in the prevalence of anti-spike IgG ≥ 30 BAU/mL (5%, 1/20 vs. 45%, 9/20, p = 0.008). When considering all patients, with or without longitudinal follow-up, prevalence of anti-spike IgG ≥ 30 BAU/mL after the third dose was 39% (63/160) in kidney transplant recipients and 50% (10/20) in patients treated for CLL. Overall, this suggests that a third dose of COVID-19 vaccine in immunocompromised patients can increase antibody levels. Still, this increase might not be clinically relevant because few patients reached anti-spike IgG levels ≥ 30 BAU/mL, previously associated with 50% vaccine effectiveness [19] . These results are in line with other studies in kidney transplant recipients [10] [11] [12] and provide new data regarding patients with CLL.

In kidney transplant recipients, our results confirm the association between young age (<65 years) and response to COVID-19 vaccines (p = 0.02) [6, 20] and suggest a better response in patients with a history of COVID-19 (p = 0.04). In patients treated for CLL, our results confirm the association between treatment with tyrosine kinase inhibitors or venetoclax and non-response to COVID-19 vaccines (p = 0.007) [8] .

One limitation of our study is the small number of patients with longitudinal followup. Indeed, antibody responses in immunocompromised patients are probably too heterogeneous to compare groups of unpaired patients. Other limitations of our study are the lack of antibody measurements prior to vaccination, the lack of in vitro investigation of neutralizing Ab titers, especially against circulating variants, and cellular responses. Other parameters such as disease stage and other treatments, not included in this study, could also have an impact on response to COVID-19 vaccines.

Overall, we believe these results highlight the need for vaccination of the general population and the importance of upholding non-medical preventive measures to protect immunocompromised patients, especially those at higher risk of non-response to COVID-19 vaccines. 

Impact and Effectiveness of MRNA BNT162b2 Vaccine against SARS-CoV-2 Infections and COVID-19 Cases, Hospitalisations, and Deaths Following a Nationwide Vaccination Campaign in Israel: An Observational Study Using National Surveillance Data

Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years-United States

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca Vaccines on Covid-19 Related Symptoms, Hospital Admissions, and Mortality in Older Adults in England: Test Negative Case-Control Study

Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients. Transplantation

Humoral and Cellular Immunity to SARS-CoV-2 Vaccination in Renal Transplant versus Dialysis Patients: A Prospective, Multicenter Observational Study Using MRNA-1273 or BNT162b2 MRNA Vaccine

Reduced Humoral Response to MRNA SARS-Cov-2 BNT162b2 Vaccine in Kidney Transplant Recipients without Prior Exposure to the Virus

COVID-19 Vaccine Efficacy in Patients with Chronic Lymphocytic Leukemia

Efficacy of the BNT162b2 MRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia

Suboptimal Response to COVID-19 MRNA Vaccines in Hematologic Malignancies Patients

Antibody Response After a Third Dose of the MRNA-1273 SARS-CoV-2 Vaccine in Kidney Transplant Recipients With Minimal Serologic Response to 2 Doses

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series

Three Doses of an MRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Knezevic, I. WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin

Prior COVID-19 Infection and Antibody Response to Single Versus Double Dose MRNA SARS-CoV-2 Vaccination

Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays in Infected, Recovered, and Vaccinated Groups

Effect of Previous SARS-CoV-2 Infection on Humoral and T-Cell Responses to Single-Dose BNT162b2 Vaccine

Antibody Response to the BNT162b2 MRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection

Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: A Head-to-Head Comparison of Five Quantitative Assays

Correlates of Protection against Symptomatic and Asymptomatic SARS-CoV-2 Infection. medRxiv 2021

Humoral Response after SARS-Cov-2 MRNA Vaccine in a Cohort of Hemodialysis Patients and Kidney Transplant Recipients

The authors thank Vincent Roux for its participation to data collection and all the medical and paramedical staff, especially Léa Bouijoux, involved in data collection regarding this study.

The authors declare no conflict of interest.